Rigel Pharma record Q4 net income $268M with 60% sales growth, guides 2026 revenue to $275–$290M

 

• Q4 2025 revenue was $69.8M, complementing record net income performance reported for the quarter.
• Full-year 2025 revenue totaled $294.3M, reflecting the strong growth trajectory highlighted in Rigel's results.
• Rigel guides 2026 revenue to $275–$290M and expects to maintain positive net income for the year.

https://finviz.com/quote.ashx?t=RIGL&p=d